Part of UT Health San Antonio

Part of UT Health San Antonio

You are here

Carlayne Jackson | UT Health San Antonio

Contact

jacksonce@uthscsa.edu

For administrative calls, please contact:

Departments & Divisions

Research

Research profile

Clinical

Provider profile

Carlayne E Jackson, M.D., FAAN

Chair, Dept of Neurology

Professor of Neurology and Otolaryngology

Carlayne E. Jackson, MD, FAAN, is currently professor of neurology and otolaryngology at the University of Texas Health Science Center San Antonio (UTHSCSA). She also serves as Chief of the Neuromuscular section and Vice Chair of Faculty Development and Wellness.  

Jackson is a graduate of Texas A&M University, where she received a bachelor's of science degree in Chemical Engineering. She obtained her medical degree at UTHSCSA, where she subsequently completed her neurology residency training and clinical neurophysiology fellowship. She has obtained board subspecialty certification in both clinical neurophysiology and neuromuscular medicine. She is a graduate of the Executive Leadership in Academic Medicine (ELAM) program sponsored by Drexel University College of Medicine. 

Jackson serves as medical director for the South Texas ALSA Center of Excellence and the MDA ALS Research Center. She is a member of the Western ALS Study Group, Northeast ALS Research Group, and the Muscle Study Group. She has participated in over 60 multi-center clinical trials in the areas of ALS, muscular dystrophy, and myasthenia gravis and has published over 240 abstracts, journal articles, and book chapters.  Jackson currently serves as Secretary for the American Academy of Neurology (AAN) Board of Directors and is Chair of the AAN Board Planning Committee and the AAN Meeting Management Committee.  She was awarded the AAN Leading in Excellence Mentorship Award in 2017.

  • Professional Background

    Education

    • 1987 - MD - Medicine - UTHSCSA
    • 1983 - BS - Chemical Engineering - Texas A&M University

    Training

    • 1992 - Postdoctoral Fellowship - Neurophysiology - UTHSCSA
    • 1991 - Residency - Neurology - UTHSCSA
    • 1988 - Internship - Internal Medicine - UTHSCSA

    Highlights

    Texas Super Doctors
    Best Doctors in America
    Super Doctors Texas Hall of Fame

    Appointments

    • 09/2022 - Chair, Dept of Neurology - UT Health San Antonio
    • 6/2018 - Vice Chair for Faculty Development and Wellness - UT Health San Antonio, Neurology, San Antonio
    • 7/2007 - Professor w/Tenure - UTHSCSA, Otolaryngology/Head and Neck Surgery, San Antonio
    • 9/2006 - Professor w/Tenure - UTHSCSA, Neurology, San Antonio
    • 7/1991 - Staff Neurologist - Bexar County Hospital District, Medicine, San Antonio

  • Instruction & Training

    • 9/2018 - Present, Neurology Consultative Service, The University of Texas Health Science Center
    • 09/2018 - present, Research - Peripheral Neuropathy, The University of Texas Health Science Center
    • 09/2002 - Present, Clinical Medicine - Occupational Therapy Clinical Series, ALS, The University of Texas Health Science Center
    • 09/1999 - Present, Research - ACES Neurology Lab, The University of Texas Health Science Center
    • 01/1996 - Present, Clinical Medicine - South Texas ALS Clinic, The University of Texas Health Science Center
    • 09/1994 - Clinical Medicine, Clinical Medicine - Attending Service, The University of Texas Health Science Center
    • 09/1991 - Present, Clinical Medicine - Consult Service, UHS
    • 09/1991 - Present, Clinical Medicine - Neurology Faculty Backup Call
    • 09/1991 - Present, Clinical Medicine - Muscular Dystrophy Association, The University of Texas Health Science Center

  • Research & Grants

    The majority of my research has centered on the participation in multi-centered clinical trials investigating potential novel therapies to slow disease progression in ALS. In addition to multi-center trials involving potential medical therapeutics, I have also been a leader in the investigation of respiratory interventions in the management of ALS. I have been extremely involved in the American Academy of Neurology and have served on committees to publish practice guidelines in the management of ALS and quality measures.

    Research profile

    Grants

    Ongoing Research Support:

    01/01/20-01/01/2023
    Funding Agency: Mitsubishi Tanabe Pharma Development America, Inc.
    A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS).
    Role: Principal Investigator

    01/01/2020-12/01/2022
    Funding Agency: Massachusetts General Hospital / HEALEY ALS PLATFORM TRIAL PLATFORM.
    The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trialevaluating the safety and efficacy of investigational products for the treatment of ALS.
    Role: Co-Investigator

    07/01/2019-06/01/2022
    Funding Agency: University of Miami / Clinical Research In ALS – CAPTURE.
    This is an observational natural history study of patients with ALS (or a related disorder) receiving care through the multi-disciplinary ALS clinics of participating CReATe Consortium centers.
    Role: Principal Investigator

    08/01/2017-08/01/2019
    Funding Agency: Cytokinetics, Inc.
    A Phase II, Multi-Center Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study To Evaluate The Efficacy, Safety, and Tolerability of CK-2127107 In Patients With Amyotrophic Lateral Sclerosis (ALS).
    Role: Site Principal Investigator

    09/01/2017-09/01/2019
    Funding Agency: Flex Pharma, Inc.
    A Randomized, Double-Blind, Controlled, Parallel Group Study To Evaluate The Efficacy and Safety of FLX-787-ODT For Treatment of Muscle Cramps In Adult Subjects With Motor Neuron Disease.
    Role: Co-Investigator

    11/2014-Present
    Funding Agency: ALS Association, MDA, Synapse Biomedical Inc.
    Multi-Center, Randomized Controlled Study of the NeuRx Diaphragm Pacing System (DPS) In Participants with Amyotrophic Lateral Sclerosis (ALS)
    Principal Investigator

  • Service

    Department

    Development of the South Texas ALS Clinic (Director) 01/1996-Present

    School

    UT Health Physicians Board of Directors (09/2009-04/2018)
    Review Committee of the Health Science Center‘s Faculty Promotions, Tenure, and Appointments Committee, UTHSCSA, School of Medicine, Dept. of Clinical Laboratory Science (10/2015-10/2016)

    Institutional

    PTAC Review Committee 01/2015-12/2016
    Executive Committee 03/2013-06/2016

  • Publications

      PUBLICATIONS:

      Shefner JM, Al-Chalabi A, Andrews JA, Chio A, De Carvalho M, Cockroft BM, Corcia P, Couratier P, Cudkowicz ME, Genge A, Hardiman O, Heiman-Patterson T, Henderson RD, Ingre C, Jackson CE, Johnston W, Lechtzin N, Ludolph A, Maragakis NJ, Miller TM, Mora Pardina JS, Petri S, Simmons Z, Van Den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA & Rudnicki SA (2023) COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, DOI: 10.1080/21678421.2023.2216223

      Gebreiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff A, Butzner M, Chio A, Andres JA, Genge A, Hughes DA, Jackson CE, Lechtzin N, Miller TM, and Shefner JM. Health Utilities and Quality-Adjusted Life Years for Patients With Amyotrophic Lateral Sclerosis Receiving Reldesemtiv or Placebo in FORTITUDE-ALS. Journal of Medical Economics March 2023. https://doi.org/10.1080/13696998.2023.2192588

      Jackson CE, Jones LK Jr, Klein BC, Rost NR, Benish SM, Levi BT, Gross RA; 2019–2021 AAN and AANI Boards of Directors and the AAN Executive Team. Futures Planning at the AAN: Approach and Initial Outcome. Neurology. 2021 Jun 1;96(22):1032-1040. doi: 10.1212/WNL.0000000000012031. PMID: 35833271; PMCID: PMC8205468.

      Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, Chiò A, Andrews JA, Genge, A Jackson CE, Lechtzin N, Miller TM & Shefner JM. (2022) MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, DOI: 10.1080/21678421.2022.2154678

      Genge A, Pattee GL, Sobue G, Aoki M, Yoshino H, Couratier P, Lunetta C, Petri S, Selness D, Bidani S, Hirai M, Sakata T, Salah A, Apple S, Wamil A, Kalin A, Jackson CE. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle Nerve. 2023 Feb;67(2):124-129. doi: 10.1002/mus.27768. Epub 2022 Dec 28. PMID: 36504406.

      Kim HS, Son J, Lee D, Tsai J, Wang D, Chocron ES, Jeong S, Kittrell P, Murchison CF, Kennedy RE, Tobon A, Jackson CE, Pickering AM. Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset. BMC Neurol. 2022 Feb 21;22(1):62. doi: 10.1186/s12883-022-02586-5. PMID: 35189854; PMCID: PMC8862222.

      Granit V, Grignon. AL, Wuu J, Katz J, Walk D, Hussain S, Hernandez J, Jackson CE, Caress J, Yosick T, Smider N, Benatar M. Harnessing the Power of the Electronic Health Record for ALS Research and Quality Improvement: CReATe CAPTURE-ALS and the ALS Toolkit. Muscle & Nerve 2022 Feb; 65(2):154-161. https://doi.org/10.1002/mus.27454

      Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, Chase M, Sherman A, You H, Drake K, Andrews J, Shefner J, Chibnik L, Vestrucci M, Cudkowicz ME, Healey ALS Platform Trial Study Group. Adaptive Platform Trials for ALS Annals of Neurology 2021 Dec.

      Cudkowicz ME, Lindborg SR, Goyal NA, Miller RG, Burford MJ, Berry JD, Nicholson KA, Mozaffar T, Katz JS, Jenkins LJ, Baloh RH, Lewis RA, Staff NP, Owegi MA, Berry DA, Gothelf Y, Levy YS, Aricha R, Kern RZ, Windebank AJ, Brown RH. A Randomized Placebo-Controlled Phase 3 Study of Mesenchymal Stem Cells Induced To Secrete High Levels of Neurotrophic Factors In Amyotrophic Lateral Sclerosis Muscle and Nerve 2021 Dec.

      Jackson CE, Heiman-Patterson, TD, Sherman M, Daohai YU, Kasarskis EJ and The Nutrition/NIV Study Group. Factors Associated With Noninvasive Ventilation Compliance In Patients With ALS/MND Amyotrophica Lateral Sclerosis an Frontotemporal Degeneration 2021 Aug;22(1):40-47.

      Heiman-Patterson TD, Khazaal O, Yu D, Sherman ME, Kasarskis EJ, Jackson CE & the PEG NIV Study Group. Pulmonary Function Decline In Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2021 Aug;22(1):54-61.

      Heiman-Patterson TD, Sherman MS, Yu D, Jackson CE, George A, Kasarskis EJ and THE NUTRITION/NIV STUDY GROUP. Use of A New ALS Specific Respiratory Questionnaire: The ARES Score Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2021 Aug;22(1):48-53.

      Rudnicki SA, Andrews JA, Genge A, Jackson CE, Lechtzin N, Miller TM, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Shefner JM & ON BEHALF OF THE FORTITUDE-ALS STUDY GROUP (2022). Prescription and Acceptance of Durable Medical Equipment in FORTITUDE-ALS, A Study of Reldesemtiv in ALS: Post Hoc Anaylses of A Randomzed, Double-Blind, Placebo-Controlled Clinical Trial, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 23:3-4, 263-270, DOI: 10.1080/21678421.2021.1946083 Jul 2021

      Rudnicki SA, Andrews JA, Genge A, Jackson CE, Lechtzin N, Miller TM, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA & Shefner JM o behalf of The Fortitude-ALS Study Group. Prescription and Acceptance of Durable Medical Equipment in FORTITUDE-ALS, A Study of Reldesemtiv In ALS: Post Hoc Analyses of A Randomised, Double-Blind, Placebo-Controlled Clinical Trial Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (IAFD) 2021 Jul.

      Jackson CE, Jones LK Jr, Klein BC, Rost NR, Benish SM, Levi BT, Gross RA; 2019–2021 AAN and AANI Boards of Directors and the AAN Executive Team. Futures Planning at the AAN: Approach and Initial Outcome. Neurology. 2021 Jun 1;96(22):1032-1040. doi: 10.1212/WNL.0000000000012031. PMID: 35833271; PMCID: PMC8205468.

      Place K, Benatar M, Wuu J, Rampersaud E, Hennessy L, Van Deerlin VM, Grossman M, Irwin DJ, Elman L, McCluskey L, Quinn C, Granit V, Statland JM, Burns TM, Ravits J, Swenson A, Katz J, Pioro EP, Jackson CE, Caress J, So Y, Maiser S, Walk D, Lee EB, Trojanowski JQ, Cook P, Gee J, She J, Naj AC, Rademakers R, The CReATe Consortium, Chen W, Wu G, Taylor JP, McMillan CT. Machine Learning Suggests Polygenic Risk For Cognitive Dysfunction In Amyotrophic Lateral Sclerosis EMBO Molecular Medicine 2021 Jan;13(1).

      Paganoni S, Hendrix S, Dickdson SP, Knowlton N, Macklin EA, Berry JD, Elliott MA, Maiser S, Kara C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson TD, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Hall M, Kittle G, Eydinov M, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, St Pierre ME, Tustison E, Vigneswaran P, Walker J, You H, Chan J, Wittes J, Yu ZF, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Long-Term Survival of Participants In The CENTAUR Trial of Sodium Phenylbutyrate-Taurursodiol In Amyotrophic Lateral Sclerosis Muscle & Nerve 2020 Oct;63:31-39.

      Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott M, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, HeimanPatterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson K, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis New England Journal of Medicine 2020 Sep;383:919-930.

      Rivner MH, Quarles BM, Pan J, Yu Z, Howard JF, Corse A, Dimachkie MM, Jackson CE, Vu T, Small G, Lisak RP, Belsh J, Lee I, Nowak RJ, Baute V, Scelsa S, Fernandes A, Simmons Z, Swenson A, Baron RJ, Sanka RB, Gooch C, Ubogu E, Caress J, Pasnoor M, Xu H, Mei L, LRP4 Research Group. Clinical Features of LRP4/Agrin Antibody Positive Myasthenia Gravis: A Multi-center Study Muscle & Nerve 2020 Sep;62(3):333-343.

      Lee I,Kuo HC, Aban IB, Cutter GR, McPherson T, Kaminski HJ, Susan J, Strobel P, Ofer J, Rea G, Heckmann J, Evil A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun Said R, Chalk C, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Cruz MW, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Vershuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Baron RJ, Tandan R, Mozaffar T, Conwit R, Mkinisman G, Sonett JR, Wolfe GI. Minimal Manifestation Status and Prednisone Withdrawal In The MGTX Trial Neurology 2020 Aug;95(6).

      Benatar M, Zhang L, Wang L, Granit V, Statland J, Baron R, Swenson, Ravits J, Jackson CE, Burns T, Trivedi J, Pioro E, Caress J, Katz J, McCauley J, Rademakers R, Malaspina A, Ostrow L, and Wuu, J, on behalf of the CReATe Consortium. Validation of Serum Neurofilament As Prognostic and Pharmacodynamic Biomarkers for ALS Neurology 2020 Jul;95(1).

      Benatar M, Zhang L, Wang L, Granit V, Statland JM, Baron RJ, Swenson AJ, Ravits JM, Jackson CE, Burns TM, Trivedi J, Pioro EP, Caress JB, Katz J, MCauley J, Rademakers R, Malaspina A, Ostrow LW, Wuu J. Validation of Serum Neurofilaments as Prognostic & Potential Pharmacodynamic Biomarkers for ALS Neurology 2020 Jul;95(1):e59-e69.

      Andrews J, Jackson C, Heiman-Patterson T, Bettica P, Brooks BR, Pioro EP. RealWorld Evidence of Riluzole Effectiveness In Treating Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2020 Jun;21(7-8):509-518.

      Isaacson SH, Ondo W, Jackson CE, Trosch RM, Molho E, Pagan F, Lew M, Dashtipour K, Clinch T, Espay AJ, MYSTICOL Study Group. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults JAMA Neurology 2020 Apr;77(4):461-469.

      Shahid N, Jackson CE. Unknown Significance - I Think Not. Poster presentation at 42nd Annual Carrell-Krusen Neuromuscular Symposium Wolters Kluwer; 2020 Mar. (Clinical Neuromuscular Disease; vol. 21, no. 3).

      Shahid N, Donnelly J, Bhavaraju-Sanka R, Jackson CE. A Rare Case of Congenital Muscular Dystrophy. Poster presentation at the 42nd Annual CarrellKrusen Neuromuscular Symposium Wolters Kluwer; 2020 Mar. (Clinical Neuromuscular Disease; vol. 21, no. 3).

  • Clinical

    Provider profile

    Board Certifications

    • 2011 - Neurology with Added Qualifications in Neuromuscular Medicine - ABPN
    • 1993 - American Board of P&N/Neurology